Path Ex

Executive Summary

Path Ex is a private, clinical-stage medical device company based in San Francisco, developing a novel blood purification therapy for sepsis. Its lead product, CycloPE®, is an extracorporeal device designed to directly and rapidly remove bacteria from the bloodstream, addressing a critical unmet need in sepsis management where current treatments focus on supportive care and antibiotics. The device has received FDA Breakthrough Device Designation, recognizing its potential to provide a more effective and targeted treatment. Sepsis remains a leading cause of death worldwide, and the ability to mechanically clear pathogens could significantly improve outcomes, reduce mortality, and lower healthcare costs. Path Ex is advancing CycloPE through regulatory pathways and preparing for pivotal clinical trials to validate safety and efficacy. The company has yet to disclose total funding or valuation, but its innovative approach and regulatory designation position it favorably for future investment and partnerships. Upcoming catalysts include the initiation or completion of pivotal trials, which could provide key efficacy data and support regulatory submissions. Additionally, Path Ex may seek strategic collaborations or Series B financing to scale manufacturing and commercialize the device. While early-stage, the technology's differentiation and the urgent clinical need offer substantial upside. Success in trials could lead to a paradigm shift in sepsis treatment, making Path Ex a compelling opportunity in the medtech space.

Upcoming Catalysts (preview)

• Q1 2027Pivotal Trial Enrollment Completion70% success
• Q2 2026Series B Funding Round60% success
• Q3 2026FDA Breakthrough Device Designation Expansion for Pediatric Sepsis50% success